Evidence map›Paper›PMID 36725015›Full record

ReviewBMJ (Clinical research ed.)2023

Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews.

Giovanni E Ferreira, Christina Abdel-Shaheed, Martin Underwood, Nanna B Finnerup, Richard O Day, Andrew McLachlan, Sam Eldabe, Joshua R Zadro, Christopher G Maher

Open access · hybridAbstract readReview
In one paragraph

Review in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 6 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 6 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Giovanni E FerreiraSydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia giovanni.ferreira@sydney.edu.au.ORCID 0000-0002-8534-195X
Christina Abdel-ShaheedSydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0003-1258-5125
Martin UnderwoodWarwick Clinical Trials Unit, University of Warwick, Coventry, UK.ORCID 0000-0002-0309-1708
Nanna B FinnerupDanish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-5541-0240
Richard O DaySt Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0002-6045-6937
Andrew McLachlanSydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0003-4674-0242
Sam EldabeJames Cook University Hospital, Middlesbrough, UK.ORCID 0000-0002-9250-1886
Joshua R ZadroSydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0001-8981-2125
Christopher G MaherSydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0002-1628-7857
The University of Sydney · AUAarhus University · DKJames Cook University Hospital · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GBUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo provide a comprehensive overview of the efficacy, safety, and tolerability of antidepressants for pain according to condition.

designOverview of systematic reviews. DATA SOURCES: PubMed, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials from inception to 20 June 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews comparing any antidepressant with placebo for any pain condition in adults. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data. The main outcome measure was pain; for headache disorders it was frequency of headaches. Continuous pain outcomes were converted into a scale of 0 (no pain) to 100 (worst pain) and were presented as mean differences (95% confidence intervals). Dichotomous outcomes were presented as risk ratios (95% confidence intervals). Data were extracted from the time point closest to the end of treatment. When end of treatment was too variable across trials in a review, data were extracted from the outcome or time point with the largest number of trials and participants. Secondary outcomes were safety and tolerability (withdrawals because of adverse events). Findings were classified from each comparison as efficacious, not efficacious, or inconclusive. Certainty of evidence was assessed with the grading of recommendations assessment, development, and evaluation framework.

results26 reviews (156 unique trials and >25 000 participants) were included. These reviews reported on the efficacy of eight antidepressant classes covering 22 pain conditions (42 distinct comparisons). No review provided high certainty evidence on the efficacy of antidepressants for pain for any condition. 11 comparisons (nine conditions) were found where antidepressants were efficacious, four with moderate certainty evidence: serotonin-norepinephrine reuptake inhibitors (SNRIs) for back pain (mean difference -5.3, 95% confidence interval -7.3 to -3.3), postoperative pain (-7.3, -12.9 to -1.7), neuropathic pain (-6.8, -8.7 to -4.8), and fibromyalgia (risk ratio 1.4, 95% confidence interval 1.3 to 1.6). For the other 31 comparisons, antidepressants were either not efficacious (five comparisons) or the evidence was inconclusive (26 comparisons).

conclusionsEvidence of efficacy of antidepressants was found in 11 of the 42 comparisons included in this overview of systematic reviews-seven of the 11 comparisons investigated the efficacy of SNRIs. For the other 31 comparisons, antidepressants were either inefficacious or evidence on efficacy was inconclusive. The findings suggest that a more nuanced approach is needed when prescribing antidepressants for pain conditions. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022311073.

Indexed as

Serotonin and Noradrenaline Reuptake InhibitorsAdultAntidepressive AgentsHumansNorepinephrinePainSelective Serotonin Reuptake InhibitorsSystematic Reviews as TopicAntidepressive AgentsNorepinephrineSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake Inhibitors

Identifiers

PMID36725015
PMCPMC9887507
OpenAlexW4318918369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.